{
    "clinical_study": {
        "@rank": "151313", 
        "acronym": "BEGIN\u2122", 
        "arm_group": [
            {
                "arm_group_label": "Insulin degludec", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Insulin glargine", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Africa, Asia, Europe, North and South America. The aim of the\n      trial is to compare efficacy and safety of insulin degludec and insulin glargine in insulin\n      na\u00efve subjects with type 2 diabetes."
        }, 
        "brief_title": "A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin na\u00efve Subjects With Type 2 Diabetes", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months\n\n          -  Insulin na\u00efve subjects (Allowed are: previous short term insulin treatment up to 14\n             days; treatment during hospitalisation or during gestational diabetes is allowed for\n             periods longer than 14 days)\n\n          -  Current treatment: metformin monotherapy or metformin in any combination with an\n             insulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase IV (DPP-IV)\n             inhibitor, alfa-glucosidase-inhibitors (acarbose) with unchanged dosing for at least\n             3 months prior to randomisation (Visit 2) with the minimum doses stated: metformin:\n             alone or in combination (including fixed combination) 1500 mg daily, or maximum\n             tolerated dose (at least 1000 mg daily), insulin secretagogue (sulfonylurea or\n             glinide): minimum half of the daily maximal dose according to local labelling,\n             DPP-IV inhibitor: minimum 100 mg daily or according to local labelling,\n             alfa-glucosidase-inhibitors (acarbose): minimum half of the daily maximal dose or\n             maximum tolerated dose\n\n          -  HbA1c (glycosylated haemoglobin) 7.0-10.0% (both inclusive) by central laboratory\n             analysis\n\n          -  BMI (Body Mass Index) below or equal to 40.0 kg/m^2\n\n        Exclusion Criteria:\n\n          -  Treatment with TZDs (thiazoledinedione), or GLP-1 (glucagon-like peptide 1) receptor\n             agonists within the last 3 months prior to Visit 1 (screening)\n\n          -  Anticipated change in concomitant medication known to interfere significantly with\n             glucose metabolism, such as systemic corticosteroids, beta-blockers, MAO (monoamine\n             oxidase) inhibitors\n\n          -  Cardiovascular disease within the last 6 months prior to Visit 1 (screening) defined\n             as stroke; decompensated heart failure NYHA (New York Heart Association) class III or\n             IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass\n             graft or angioplasty\n\n          -  Any clinically significant disease or disorder, except for conditions associated with\n             type 2 diabetes mellitus, which in the Investigator's opinion could interfere with\n             the results of the trial\n\n          -  Previous participation in this trial. Participation is defined as randomised.\n             Re-screening of screening failures is allowed only once within the limits of the\n             recruitment period\n\n          -  Known or suspected hypersensitivity to trial product(s) or related products"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "833", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01849289", 
            "org_study_id": "NN1250-3587", 
            "secondary_id": "U1111-1121-5325"
        }, 
        "intervention": [
            {
                "arm_group_label": "Insulin degludec", 
                "description": "Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.", 
                "intervention_name": "insulin degludec", 
                "intervention_type": "Drug", 
                "other_name": "NN1250"
            }, 
            {
                "arm_group_label": "Insulin glargine", 
                "description": "Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.", 
                "intervention_name": "insulin glargine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 15, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35570"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92801"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lomita", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90717"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90057"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60607"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Crestview Hills", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "41017-3464"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Troy", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48098"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toms River", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08755-8050"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Smithtown", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11787"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Simpsonville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29681"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75230"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23502"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kenosha", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53142-7884"
                    }, 
                    "name": "Novo Nordisk Clinical Trial Call Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S\u00e3o Paulo", 
                        "country": "Brazil", 
                        "state": "Sao Paulo", 
                        "zip": "01244-030"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Surrey", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V3S 2N6"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100029"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310006"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Johannesburg", 
                        "country": "South Africa", 
                        "state": "Gauteng", 
                        "zip": "2193"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durban", 
                        "country": "South Africa", 
                        "state": "KwaZulu-Natal", 
                        "zip": "4091"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kiev", 
                        "country": "Ukraine", 
                        "zip": "04114"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vinnitsa", 
                        "country": "Ukraine", 
                        "zip": "21010"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Brazil", 
                "Canada", 
                "China", 
                "South Africa", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin na\u00efve Subjects With Type 2 Diabetes (BEGIN\u2122: ONCE).", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Brazil: National Health Surveillance Agency", 
                "Canada: Public Health Agency of Canada", 
                "China: Ministry of Health", 
                "Ukraine: Ministry of Health Ukraine", 
                "United States: Food and Drug Administration", 
                "South Africa: Medicines Control Council"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in HbA1c (%) (analysed by central laboratory)", 
            "safety_issue": "No", 
            "time_frame": "Week 0, week 26"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01849289"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of severe and minor treatment emergent hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "On or after the first day of exposure to randomised trial drug (week 0) and no later than 7 days after last exposure to randomised trial drug (week 27)"
            }, 
            {
                "measure": "Change from baseline in FPG (fasting plasma glucose) (analysed by central laboratory)", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 26"
            }, 
            {
                "measure": "Within-subject variability as measured by coefficient of variation (CV%) in pre-breakfast SMPG (self-measured plasma glucose)", 
                "safety_issue": "No", 
                "time_frame": "Week 26"
            }, 
            {
                "measure": "Responder for HbA1c (below 7.0%) at end of trial without severe and minor hypoglycaemic episodes", 
                "safety_issue": "No", 
                "time_frame": "Week 26"
            }, 
            {
                "measure": "Number of treatment emergent AEs (adverse events)", 
                "safety_issue": "No", 
                "time_frame": "On or after the first day of exposure to randomised trial drug (week 0) and no later than seven days after last exposure to randomised trial drug (week 27)"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}